Advertisement

Psychopharmacology

, Volume 124, Issue 1–2, pp 159–167 | Cite as

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

  • C. M. BeasleyJr
  • T. Sanger
  • W. Satterlee
  • G. Tollefson
  • P. Tran
  • S. Hamilton
Original Investigation

Abstract

Olanzapine is a potential new “atypical” antipsychotic agent. This double-blind, acute phase study compared two doses of olanzapine [1 mg/day (Olz1.0); 10 mg/day (Olz10.0)] with placebo in the treatment of 152 patients who met the DSM-III-R criteria for schizophrenia and had a Brief Psychiatric Rating Scale (BPRS)-total score (items scored 0–6) ≥24. In overall symptomatology improvement [BPRS-total score and Positive and Negative Syndrome Scale (PANSS)-total score], Olz10.0 was statistically significantly superior to placebo. In positive symptom improvement (PANSS-positive score, BPRS-positive score), Olz10.0 was statistically significantly superior to placebo. In negative symptom improvement (PANSS-negative score), Olz10.0 was statistically superior to placebo. Olz 1.0 was clinically comparable to placebo in all efficacy comparisons. The only adverse event to show an overall statistically significant incidence difference was anorexia (reported for 10% of placebo-treated and 0% of Olz10.0-treated patients). The Olz10.0-treated patients improved over baseline with respect to parkinsonian and akathisia symptoms, and these changes were comparable with those observed with placebo. There were no dystonias associated with Olz10.0 treatment. At endpoint, the incidence of patients with elevated prolactin values did not differ statistically significantly between placebo-treated and Olz10.0-treated patients. Olanzapine appears to be not only safe and effective, but a promising atypical antipsychotic candidate.

Key words

Olanzapine Placebo Acute Double-blind Atypical Schizophrenia Antipsychotic 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association Task Force on Nomenclature and Statistics (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. APA Press, Washington, DCGoogle Scholar
  2. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676Google Scholar
  3. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD Study Group (1995) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (in press)Google Scholar
  4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1995) Radioreceptor binding profile of the atypical olanzapine. Neuropsychopharmacology (in press)Google Scholar
  5. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53Google Scholar
  6. Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 77:87–93Google Scholar
  7. Guy W (1976) ECDEU assessment manual for psychopharmacology, revised version. US Department of Health, Education and Welfare, Bethesda, MarylandGoogle Scholar
  8. Hemrick-Luecke SK, Bymaster FP, Falcone JF, Moore NA, Tye NC, Fuller RW (1993) Effect of olanzapine on rat brain receptor binding, acetylcholine levels and monoamine turnover. Tenth Annual Society for Neuroscience Meeting, Indianapolis Chapter, Indianapolis, Ind. Twenty-third Annual Society for Neuroscience Meeting, Washington, DC, 21 May, 7–12 NovemberGoogle Scholar
  9. Kay SR, Opler LA, Fiszbein A (1986) Positive and negative syndrome scale (PANSS) manual. Multi-Health Systems, North Tonawanda, New YorkGoogle Scholar
  10. Meltzer HY (1992) The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 1–13Google Scholar
  11. Montgomery S, Beasley CM, Tye NC (1992) Olanzapine: an open label study in schizophrenia. Second International Conference on Schizophrenia, Vancouver, BC, 19–22 JulyGoogle Scholar
  12. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 262:545–551Google Scholar
  13. Moore NA, Calligaro DO, Wong TD, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281–293Google Scholar
  14. Moore NA, Rees G, Sanger G, Tye NC (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5:196–202Google Scholar
  15. Rasmussen K, Stockton ME (1993) Olanzapine, a novel atypical antipsychotic, has electrophysiological effects on A9 and A10 dopamine neurons similar to clozapine. American College of Neuropsychopharmacology, Honolulu, Hawaii, 12–17 DecemberGoogle Scholar
  16. SAS Institute (1990) SAS/STAT user's guide, vol 1&2, 4th edn, 6th version. SAS Institute, Cary, New YorkGoogle Scholar
  17. Seeman P, Van Tol HHM (1993) Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 6:602–608Google Scholar
  18. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19Google Scholar
  19. Stockton ME, Rasmussen K (1993) A comparison of olanzapine and clozapine effects on dopamine neuronal activity: an electrophysiological study. Twenty-Third Annual Meeting of the Society for Neuroscience, Washington, DC, 7–12 NovemberGoogle Scholar
  20. Stockton ME, Rasmussen K (1995) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, an A9 and A10 dopamine neurons. Neuropsychopharmacology (in press)Google Scholar
  21. Tye NC, Moore NA, Rees G, Sanger G, Calligaro DO, Beasley CM (1992) Preclinical pharmacology of olanzapine: a novel “atypical” antipsychotic agent. Second International Conference on Schizophrenia, Vancouver, BC, 18–22 JulyGoogle Scholar
  22. Wong DT, Moore NA, Calligaro O, Bymaster FP, Seeman P (1993) The preclinical pharmacology of olanzapine, a novel antipsychotic. Ninth World Congress of Psychiatry, Rio de Janeiro, Brazil, 6–12 JuneGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • C. M. BeasleyJr
    • 1
  • T. Sanger
    • 1
  • W. Satterlee
    • 1
  • G. Tollefson
    • 1
  • P. Tran
    • 1
  • S. Hamilton
    • 1
  1. 1.Psychopharmacology Division, Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA

Personalised recommendations